Zurcher Kantonalbank Zurich Cantonalbank Has $1.21 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 43.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 20,123 shares of the company’s stock after purchasing an additional 6,102 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Apellis Pharmaceuticals were worth $1,205,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. IFP Advisors Inc lifted its position in Apellis Pharmaceuticals by 95.8% during the third quarter. IFP Advisors Inc now owns 3,806 shares of the company’s stock worth $145,000 after acquiring an additional 1,862 shares during the last quarter. Avior Wealth Management LLC lifted its position in Apellis Pharmaceuticals by 37.5% during the third quarter. Avior Wealth Management LLC now owns 3,806 shares of the company’s stock worth $145,000 after acquiring an additional 1,039 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Apellis Pharmaceuticals by 48.6% during the third quarter. Commonwealth Equity Services LLC now owns 6,922 shares of the company’s stock worth $263,000 after acquiring an additional 2,263 shares during the last quarter. Sippican Capital Advisors lifted its position in Apellis Pharmaceuticals by 77.8% during the third quarter. Sippican Capital Advisors now owns 15,834 shares of the company’s stock worth $602,000 after acquiring an additional 6,930 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Apellis Pharmaceuticals by 0.8% during the third quarter. Bank of New York Mellon Corp now owns 360,287 shares of the company’s stock worth $13,705,000 after acquiring an additional 2,998 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on APLS. Oppenheimer raised their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Mizuho reaffirmed a “neutral” rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $92.00 target price on shares of Apellis Pharmaceuticals in a report on Friday. UBS Group raised their target price on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, The Goldman Sachs Group raised their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $77.93.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $49.86 on Friday. The company’s 50 day simple moving average is $58.21 and its 200 day simple moving average is $57.30. The stock has a market capitalization of $6.01 billion, a price-to-earnings ratio of -11.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals, Inc. has a 1 year low of $19.83 and a 1 year high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same period last year, the firm posted ($1.50) earnings per share. As a group, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 250,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the sale, the chief executive officer now owns 313,662 shares of the company’s stock, valued at $20,108,870.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now directly owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 381,011 shares of company stock valued at $23,463,657. 7.50% of the stock is currently owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).